For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
2
KYGEVVI® (doxecitine and doxribtimine)
Thymidine Kinase 2 Deficiency
Pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d): a multicenter retrospective chart review study
phase
3
BIMZELX® (bimekizumab-bkzx)
Plaque Psoriasis
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Patient diagnostic journey and time to diagnosis in axial spondyloarthritis: A retrospective cohort study
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations
phase
4/RWE
Generalized Myasthenia Gravis
What Patients Don’t Say and Physicians Don’t Ask: A Needs Assessment in MG Integrating Patient and Healthcare Professional Perspectives
phase
3
RYSTIGGO® (rozanolixizumab-noli)
Generalized Myasthenia Gravis
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
phase
3
BIMZELX® (bimekizumab-bkzx)
Hidradenitis Suppurativa
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II
phase
2
BIMZELX® (bimekizumab-bkzx)
Hidradenitis Suppurativa
Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II
phase
4/RWE
Generalized Myasthenia Gravis
Treatment patterns and disease burden of juvenile myasthenia gravis in the United States: a cohort study using healthcare claims databases (RWE0816)